Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer

CRANBURY, N.J., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Steve Carchedi as Chief Executive Officer. Mr. Carchedi will lead the Company forward towards commercialization of the Company's technology and products. Steve will also be appointed to the Board of Directors.

Founding CEO Robert Shorr Ph.D. D.I.C. will continue his role as Chief Scientific Officer.

Mr. Carchedi has over 30 years of industry experience in bringing products to market and commercialization. During his career, Mr. Carchedi has led in the commercialization of multiple oncology products that are on the market today as the standard of care. Most recently, he was President, North America for Mallinckrodt Pharmaceuticals, the pharmaceutical business of Covidien Plc, where he led commercial operations for the spinout of Mallinckrodt into a separate public company.

Prior to joining Mallinckrodt, Mr. Carchedi was the Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for leading worldwide marketing for GE's Medical and Molecular Diagnostics business. Prior to GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (Bortezomib) indicated for the treatment of Multiple Myeloma in over 80 countries. He served as Director of the Oncology Product group for Eli Lilly and Co. where he led Lilly's oncology strategy and in commercializing of GEMZAR® (Gemcitabine) and ALIMTA® (Pemetrexed), two leading chemotherapies on the market today.

Commenting on the appointment, Dr. Shorr stated, "As me move beyond clinical research and into clinical development with first-in-class first-in-man anticancer drugs with new mechanisms of action, we are excited to have someone of Steve's caliber and experience join Cornerstone to lead us through the next stages of growth required for commercialization. His proven track record of successfully leading companies through development, marketing and launch of products, specifically within oncology, and driving value and growth once commercialized is a key component in our strategy for growth. We look to his skillset as a critical asset as we move ahead in furthering development of our lead product candidate, CPI-613, and our product pipeline and technology platforms."

Mr. Carchedi said, "This is a prime opportunity to join a dedicated and experienced team of individuals who have taken a novel cancer metabolism-based approach with potential utility in a broad spectrum of cancer types and launched an innovative company capable of a game changing impact in the treatment of cancer by focusing on its new and unique platform technology. I look forward to working with the team as we advance the clinical development of drug candidates from our altered energy metabolism directed platform and strive to bring an effective treatment option to the market for patients suffering from the more difficult to treat disease."

Currently, Mr. Carchedi serves on the Board of Directors of Sunesis Pharmaceuticals, Bionumerick Pharmaceuticals and on the Strategic Advisory Board for PCAsso Diagnostics LLC. He is a member of the Chief Marketing Officer Council (CMOC), and served on the Ontario Institute of Cancer Research Commercial Committee (OICR) and on the Pharmaceutical Industry Board of the American Pediatric Family Foundation.

Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two independent technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphan lipid nanoemulsion based drug delivery system. www.cornerstonepharma.com .

Safe Harbor Statement

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Investor Contacts: David Burke The Ruth Group (646) 536-7009 Media Contact: Kirsten Thomas The Ruth Group (646) 536-7014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 139

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 184

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 168

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 108

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 79

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into National HealthCare Corporation by Kaskela Law

Updated Category News Views 203

Kaskela Law LLC Announces Investigation Kaskela Law LLC has recently launched an investigation into National HealthCare Corporation (NYSE: NHC) on behalf of its shareholders. This inquiry seeks to determine if the company or its executives have violated securities laws or breached their fiduciary duties in light of recent corporate actions. Investigation Objectives The...

Continue Reading
HOPE Therapeutics Expands Its Reach in Florida’s Mental Health Care

Updated Category News Views 161

HOPE Therapeutics Welcomes Cohen & Associates to the Network In an exciting advancement, HOPE Therapeutics, Inc. has recently integrated Cohen & Associates, LLC into its expanding professional framework, aimed at revolutionizing the landscape of interventional psychiatry. This noteworthy inclusion signals a meaningful step in enhancing mental health services across...

Continue Reading
Abdullah Abdin Ready Mix Concrete's Historic Certification Milestone

Updated Category News Views 217

Abdullah Abdin Ready Mix Concrete Announces Historic Achievement Setting new standards in sustainability and innovation, Abdullah Abdin Ready-Mix Concrete has proudly achieved the prestigious Concrete Sustainability Council (CSC) certification. This recognition establishes the company as the first ready-mix concrete firm in the MENA region to receive such an influential...

Continue Reading
The Tragic Shooting of Charlie Kirk: National Outrage Ensues

Updated Category News Views 393

The Shocking Assassination of Charlie Kirk Conservative political activist Charlie Kirk was tragically shot and killed while addressing a gathering. This shocking incident has ignited a series of investigations and public responses, leading to numerous political reactions across the nation. Details Surrounding the Incident The violent act took place during Kirk's speech,...

Continue Reading
Cibus Global Ltd. Faces Market Challenges with Stock Dip

Updated Category News Views 129

Cibus Global Ltd. Faces Significant Stock Decline In recent trading sessions, Cibus Global Ltd. (CBUS) stock encountered a dramatic decline, hitting a 52-week low of $2.36. This notable drop is stark when compared to its previous high of $23.18, showing a staggering reduction of approximately 88.48% over the past year. The plummeting share price has raised alarms among...

Continue Reading